plerixafor has been researched along with Adenoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avagliano, L; Beretta, E; Bulfamante, GP; Corbetta, S; Costa, E; Creo, P; Guarnieri, V; Scillitani, A; Soldati, L; Spada, A; Steffano, GB; Verdelli, C; Vicentini, L | 1 |
| Koketshu, K; Nomura, R; Teramoto, A; Yoshida, D | 1 |
2 other study(ies) available for plerixafor and Adenoma
| Article | Year |
|---|---|
Tumour-associated fibroblasts contribute to neoangiogenesis in human parathyroid neoplasia.
Topics: Adenoma; Benzylamines; Coculture Techniques; Cyclams; Fibroblasts; Gene Expression; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Immunohistochemistry; Mesenchymal Stem Cells; Neovascularization, Pathologic; Parathyroid Neoplasms; Signal Transduction; Stromal Cells; Tumor Cells, Cultured; Tumor Microenvironment | 2015 |
The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells.
Topics: Adenoma; Animals; Benzylamines; beta Carotene; Cell Hypoxia; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Growth Hormone; Heterocyclic Compounds; Humans; Middle Aged; Oligonucleotide Array Sequence Analysis; Pituitary Neoplasms; Rats; Receptors, CXCR4; RNA, Messenger; RNA, Small Interfering; Statistics as Topic | 2010 |